Related Experiment Video

Updated: Aug 9, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference

Christine Damm-Welk1, Uta Fuchs, Wilhelm Wössmann

  • 1Pediatric Hematology & Oncology, Children's University Hospital Giessen, Feulgenstr. 12, 35392 Giessen, Germany.

Seminars in Cancer Biology
|October 18, 2003
PubMed

Insights

RNA interference (RNAi) offers a promising strategy for targeting chromosomal translocations in leukemias and lymphomas. This gene-silencing approach aims to disable oncogenes activated by these translocations, presenting a novel therapeutic avenue.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Leukemias and lymphomas frequently exhibit non-random chromosomal translocations.
  • These translocations activate oncogenes or form chimeric genes, driving cancer development.
  • Such genetic abnormalities are considered key drivers of these hematologic malignancies.

Purpose of the Study:

  • To explore RNA interference (RNAi) as a therapeutic strategy.
  • To target the specific fusion sites created by chromosomal translocations.
  • To evaluate RNAi-based approaches for treating leukemias and lymphomas.

Main Methods:

  • Discussion of RNA interference (RNAi) mechanisms.
  • Focus on targeting fusion sites of chromosomal translocations.
  • Review of gene-silencing strategies in hematologic cancers.

Main Results:

  • Chromosomal translocations are direct initiators and maintainers of malignancy.
  • RNAi presents a viable method for gene silencing.
  • Targeting translocation fusion sites can potentially inhibit cancer progression.

Conclusions:

  • RNA interference (RNAi) holds potential as a future treatment for leukemias and lymphomas.
  • Targeting specific translocation fusion sites is a key strategy.
  • Gene-silencing therapies offer a novel approach to hematologic cancer treatment.

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...